


### Quarterly performance



#### Commentary

The ASX200 Healthcare Index was up 13% in the last quarter, as consumer confidence returns equity markets improved across the board. The healthcare index performance was further driven by widespread product innovation and an uptick in M&A.

Key movers included, Sigma Healthcare, a leading pharmacy retailer and wholesaler whose share price increased 46% QoQ after announcing its merger with Chemist Warehouse. 4DMedical, a developer of lung imaging technology rose 59%, with its announcement of FDA clearance for its CT lung ventilation analysis software (LVAS) product.

Healthcare M&A activity remains strong, albeit some processes having been paused.

### Quarterly M&A & other news

Date	Description
21-Dec-23	<b>Pacific Smiles</b> , a dental centre operator, rejects a \$223m buyout proposal from <b>Genesis Capital</b> which currently owns 18.75% of the register
18-Dec-23	<b>Intermediate Capital Group</b> , has acquired <b>Cura Day Hospitals</b> , an Australian owner of day surgeries, eye surgeries and endoscopy units for A\$500m
11-Dec-23	<b>Sigma Healthcare</b> announced the reverse merger with <b>CWG Group</b> , the owner of <b>Chemist Warehouse</b> , implying a combined market cap of A\$8.8bn
11-Dec-23	<b>4DMedical</b> (ASX:4DX), a developer of lung imaging and diagnostics tools announced the acquisition of Imbio, a US based complementary lung diagnostics business for approximately A\$38.5m upfront, plus a contingent earnout
29-Nov-23	<b>myHomecare</b> one of Australia's largest in-home care providers owned by <b>Quadrant Private Equity</b> , is progressing with its auction with bids expected at A\$400m
14-Nov-23	<b>Wyvern Health</b> , an Australian hospital operator, is looking for investors in a A\$25m equity raise. Equity will be used to purchase new equipment
11-Nov-23	<b>Ramsay Health Care</b> (ASX:RHC), a global hospital operator, and Malaysian conglomerate <b>Sime Darby</b> (KLSE:SIME) have agreed to sell their joint hospital unit to <b>Columbia Asia Healthcare</b> for 5.7bn ringgit (A\$1.9bn)
01-Nov-23	<b>DoctorSquare</b> , an afterhours GP care provider backed by <b>MA Financial</b> , has acquired <b>24-7 Healthcare</b> from <b>Crescent Capital</b> for A\$20m
01-Nov-23	<b>Australian Clinical Labs</b> (ASX:ACL) has withdrawn its offer for <b>Healius</b> (ASX:HLS) after the ACCC blocked the merger. ACL have said they are open to a deal in the future and will monitor Healius closely
31-Oct-23	<b>Crescent Capital Partners</b> is believed to have acquired a non-controlling stake in <b>Walski Clinical Research</b> a local clinical trials business, for an undisclosed amount
22-Oct-23	<b>Medibank</b> (ASX:MPL) is looking to increase its shareholding in GP clinics business, <b>Myhealth Medical</b> to buyout its largest shareholder, founder James Liang
15-Oct-23	<b>Bain Capital</b> is bidding for <b>BlueCross Aged Care</b> , a Melbourne residential aged care provider. BlueCross operates 31 aged care residences in Victoria, housing more than 2,600 residents
13-Oct-23	<b>EQT</b> is set to acquire <b>VetPartners</b> after it's winning bid of A\$1.4bn. VetPartners comprises more than 1300 vets, and over 3000, nurses and support staff. <b>EQT</b> is looking to raise A\$500m in debt to fund the deal.

Sources: Capital IQ, Mergermarket, press reports, AFR

## Largest 40 ASX-listed healthcare companies by market capitalisation (December 2023)

Company	Market capitalisation (A\$m)	Share price (A\$)	Share price performance (%)			Premium / (discount) to 52 week (%)		Premium / (discount) to VWAP (%)			Multiples (FY24F) <sup>(1)</sup>		
			Last quarter	Year-to-date	Last 12 months	High	Low	1 month	3 months	6 months	EV/Revenue	EV/EBITDA	P/E
1 CSL	138,479	286.65	14%	n.a.	n.a.	(9%)	25%	4%	12%	10%	7.3x	21.8x	31.7x
2 ResMed	37,117	252.35	10%	(18%)	(18%)	(29%)	30%	50%	67%	57%	5.7x	17.9x	23.9x
3 Cochlear	19,561	298.67	17%	46%	46%	(1%)	49%	2%	12%	16%	8.8x	33.8x	52.9x
4 Sonic Healthcare	15,296	32.08	8%	7%	7%	(13%)	14%	3%	7%	2%	2.0x	10.3x	24.0x
5 Fisher & Paykel	12,802	21.92	9%	4%	4%	(16%)	16%	0%	(1%)	(3%)	7.9x	28.4x	50.4x
6 Ramsay Health Care	12,018	52.61	1%	(19%)	(19%)	(24%)	13%	5%	4%	1%	1.5x	11.2x	37.9x
7 Pro Medicus	10,010	95.83	15%	73%	73%	(1%)	78%	4%	11%	20%	n.m.	n.m.	n.m.
8 EBOS	6,326	32.98	3%	(19%)	(19%)	(24%)	5%	(3%)	(7%)	(8%)	0.6x	11.5x	21.2x
9 Telix Pharmaceuticals	3,263	10.08	(12%)	39%	39%	(21%)	73%	3%	6%	(2%)	5.4x	29.0x	39.7x
10 Neuren	3,178	24.97	126%	214%	214%	(4%)	272%	25%	64%	84%	16.0x	18.9x	25.6x
11 Ansell	3,122	25.18	14%	(11%)	(11%)	(16%)	20%	3%	10%	7%	1.5x	9.6x	18.6x
12 Summerset	2,227	9.52	-	15%	15%	(3%)	27%	6%	1%	(1%)	12.5x	15.8x	12.6x
13 Nanosonics	1,332	4.40	4%	3%	3%	(24%)	22%	(0%)	6%	2%	6.3x	n.m.	90.7x
14 Sigma Healthcare	1,255	1.01	46%	65%	65%	(26%)	70%	(2%)	5%	13%	0.4x	21.0x	73.2x
15 PolyNovo	1,142	1.66	27%	(18%)	(18%)	(39%)	51%	7%	21%	17%	11.5x	n.m.	n.m.
16 Regis Healthcare	978	3.25	20%	72%	72%	(1%)	130%	8%	23%	29%	1.0x	9.5x	32.7x
17 Healius	977	1.64	(29%)	(47%)	(47%)	(52%)	38%	8%	1%	(21%)	1.5x	7.0x	58.6x
18 Australian Clinical Labs	579	2.89	1%	(3%)	(3%)	(25%)	17%	4%	7%	0%	1.3x	4.6x	15.4x
19 Oceania Healthcare	511	0.71	7%	n.a.	n.a.	(16%)	15%	7%	1%	(3%)	4.0x	12.4x	8.3x
20 Monash IVF	507	1.30	3%	36%	36%	(7%)	41%	(3%)	1%	4%	2.5x	9.5x	17.1x
21 Mayne Pharma	499	6.15	89%	54%	54%	(4%)	124%	6%	30%	36%	1.0x	44.1x	n.m.
22 Clarity Pharma	498	1.90	62%	92%	92%	(7%)	181%	14%	35%	56%	n.m.	n.m.	n.m.
23 Integral Diagnostics	445	1.91	(34%)	(35%)	(35%)	(46%)	16%	3%	(1%)	(17%)	1.6x	8.4x	24.6x
24 Anteris Technologies	341	19.15	(6%)	(14%)	(14%)	(29%)	6%	(1%)	(3%)	(4%)	n.m.	n.m.	n.m.
25 AFT Pharma	341	3.25	1%	(4%)	(4%)	(11%)	7%	(3%)	(1%)	(3%)	2.0x	13.3x	20.1x
26 Botanix Pharma	294	0.19	58%	258%	258%	(10%)	265%	20%	27%	23%	n.m.	n.m.	n.m.
27 ImpediMed	293	0.15	(17%)	84%	84%	(40%)	159%	4%	10%	(16%)	18.6x	n.m.	n.m.
28 Volpara Health	281	1.11	52%	110%	110%	(0%)	110%	3%	11%	17%	6.9x	n.m.	n.m.
29 4DMedical	279	0.72	59%	70%	70%	(44%)	147%	(9%)	(8%)	(4%)	32.6x	n.m.	n.m.
30 Capitol Health	250	0.24	12%	(27%)	(27%)	(28%)	27%	8%	18%	11%	1.6x	7.8x	24.1x
31 Cogstate	246	1.45	(5%)	(26%)	(26%)	(41%)	27%	4%	(0%)	(2%)	2.8x	12.8x	30.2x
32 Probiotec	236	2.90	10%	34%	34%	(1%)	36%	4%	6%	8%	1.3x	7.8x	15.6x
33 Pacific Smiles	233	1.46	4%	(5%)	(5%)	(6%)	66%	20%	39%	34%	1.7x	11.2x	39.2x
34 Mach7 Technologies	191	0.79	(1%)	39%	39%	(20%)	52%	4%	12%	4%	4.7x	n.m.	n.m.
35 EBR Systems	187	0.61	(11%)	33%	33%	(55%)	33%	6%	(9%)	(22%)	n.m.	n.m.	n.m.
36 Cyclopharm	181	1.93	(32%)	65%	65%	(39%)	65%	(4%)	(20%)	(20%)	5.0x	n.m.	n.m.
37 Oneview Healthcare	160	0.24	(4%)	118%	118%	(26%)	293%	5%	6%	10%	n.m.	n.m.	n.m.
38 Paragon Care	150	0.23	32%	(29%)	(29%)	(32%)	50%	1%	15%	14%	0.8x	6.5x	10.1x
39 Vitura Health	147	0.26	(31%)	(56%)	(56%)	(60%)	19%	(3%)	(20%)	(33%)	0.9x	5.6x	9.4x
40 CurveBeam AI	133	0.42	-	n.a.	n.a.	(24%)	60%	26%	23%	9%	11.1x	n.m.	n.m.
<b>Average</b>	<b>6,902</b>		<b>13%</b>	<b>31%</b>	<b>31%</b>	<b>(22%)</b>	<b>133%</b>	<b>3%</b>	<b>8%</b>	<b>6%</b>	<b>5.6x</b>	<b>15.0x</b>	<b>31.1x</b>

## Top 10 best performers in the last quarter<sup>(2)</sup>

Company	Market capitalisation (A\$m)	Share price (A\$)	Share price performance (%)			Premium / (discount) to 52 week (%)		Premium / (discount) to VWAP (%)			Multiples (FY23F) <sup>(1)</sup>		
			Last quarter	Year-to-date	Last 12 months	High	Low	1 month	3 months	6 months	EV/Revenue	EV/EBITDA	P/E
1 Neuren	3,178	24.97	126%	214%	214%	(4%)	272%	25%	64%	84%	16.0x	18.9x	25.6x
2 Mayne Pharma	499	6.15	89%	54%	54%	(4%)	124%	6%	30%	36%	1.0x	44.1x	n.m.
3 Arovela Therapeutics	105	0.12	69%	400%	400%	(15%)	475%	10%	26%	52%	n.m.	n.m.	n.m.
4 Clarity Pharma	498	1.90	62%	92%	92%	(7%)	181%	14%	35%	56%	n.m.	n.m.	n.m.
5 4DMedical	279	0.72	59%	70%	70%	(44%)	147%	(9%)	(8%)	(4%)	32.6x	n.m.	n.m.
6 Botanix Pharma	294	0.19	58%	258%	258%	(10%)	265%	20%	27%	23%	n.m.	n.m.	n.m.
7 Volpara Health	281	1.11	52%	110%	110%	(0%)	110%	3%	11%	17%	6.9x	n.m.	n.m.
8 Sigma Healthcare	1,255	1.01	46%	65%	65%	(26%)	70%	(2%)	5%	13%	0.4x	21.0x	73.2x
9 Argenica Therapeutics	51	0.51	36%	13%	13%	(14%)	73%	1%	18%	22%	n.m.	n.m.	n.m.
10 Paragon Care	150	0.23	32%	(29%)	(29%)	(32%)	50%	1%	15%	14%	0.8x	6.5x	10.1x
<b>Average</b>	<b>659</b>		<b>63%</b>	<b>125%</b>	<b>125%</b>	<b>(15%)</b>	<b>434%</b>	<b>7%</b>	<b>22%</b>	<b>31%</b>	<b>9.6x</b>	<b>22.6x</b>	<b>36.3x</b>

## Top 10 worst performers in the last quarter<sup>(2)</sup>

Company	Market capitalisation (A\$m)	Share price (A\$)	Share price performance (%)			Premium / (discount) to 52 week (%)		Premium / (discount) to VWAP (%)			Multiples (FY23F) <sup>(1)</sup>		
			Last quarter	Year-to-date	Last 12 months	High	Low	1 month	3 months	6 months	EV/Revenue	EV/EBITDA	P/E
1 Integral Diagnostics	445	1.91	(34%)	(35%)	(35%)	(46%)	16%	3%	(1%)	(17%)	1.6x	8.4x	24.6x
2 Cyclopharm	181	1.93	(32%)	65%	65%	(39%)	65%	(2%)	(6%)	(6%)	5.0x	n.m.	n.m.
3 Alcidion	101	0.08	(32%)	(48%)	(48%)	(53%)	21%	(1%)	(3%)	(16%)	1.9x	n.m.	n.m.
4 Vitura Health	147	0.26	(31%)	(56%)	(56%)	(60%)	19%	(3%)	(20%)	(33%)	0.9x	5.6x	9.4x
5 SomnoMed	54	0.50	(29%)	(61%)	(61%)	(62%)	25%	15%	7%	(8%)	0.7x	15.5x	n.m.
6 Healius	977	1.64	(29%)	(47%)	(47%)	(52%)	38%	8%	1%	(21%)	1.5x	7.0x	58.6x
7 Next Science	99	0.34	(22%)	(50%)	(50%)	(62%)	89%	33%	29%	4%	2.7x	n.m.	n.m.
8 ImpediMed	293	0.15	(17%)	84%	84%	(40%)	159%	n.a.	n.a.	n.a.	18.6x	n.m.	n.m.
9 Micro-X	54	0.11	(16%)	(19%)	(19%)	(34%)	24%	(5%)	(13%)	(13%)	1.8x	n.m.	n.m.
10 Apiam Animal Health	52	0.29	(15%)	(54%)	(54%)	(55%)	26%	n.a.	n.a.	n.a.	n.m.	n.m.	n.m.
<b>Average</b>	<b>240</b>		<b>(26%)</b>	<b>(22%)</b>	<b>(22%)</b>	<b>(50%)</b>	<b>48%</b>	<b>6%</b>	<b>(1%)</b>	<b>(14%)</b>	<b>3.9x</b>	<b>9.1x</b>	<b>30.9x</b>

Source: Capital IQ as at 31 December 2023

Notes: (1) Calendarised to June year end. EV/EBITDA multiples are considered 'n.m.' if they are ≥50x. P/E multiples are considered 'n.m.' if they are ≥100x; (2) Top 10 best and worst performers are based on companies with a minimum market capitalisation of A\$50 million and have traded for the full quarter.